Xeris Biopharma Holdings, Inc. (XERS) Bundle
Ever wondered how a biopharmaceutical company navigates the complexities of developing and commercializing innovative therapies? Xeris Biopharma Holdings, Inc. (XERS), a growth-oriented company committed to improving patient lives, achieved record revenue topping $203 million in 2024, marking its significance in the pharmaceutical industry. With a focus on endocrinology, neurology, and gastroenterology, how does Xeris Biopharma operate and generate revenue, and what's the story behind its evolution?
Dive in to discover the history, ownership structure, and mission driving Xeris Biopharma, alongside an exploration of its business model and financial performance. You'll gain insights into its key products like Gvoke®, Recorlev®, and Keveyis®, its proprietary formulation technologies, and its strategic approach to addressing unmet medical needs, which led to a 24% revenue increase compared to the previous year.
Xeris Biopharma Holdings, Inc. (XERS) History
Xeris Biopharma's Founding Timeline
Year established
Xeris Pharmaceuticals was founded in 2005.
Original location
The company was originally located in Chicago, Illinois.
Founding team members
The founding team included individuals with expertise in drug formulation and commercialization, though specific names are not always highlighted in public records.
Initial capital/funding
Details on the initial capital and funding sources are not always publicly disclosed, but Xeris secured venture capital and private equity funding rounds to support its early research and development activities.
Xeris Biopharma's Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2017 | FDA Approval of Gvoke (glucagon injection) | Marked Xeris's transition to a commercial-stage biopharmaceutical company, addressing a critical need for treating severe hypoglycemia in diabetes patients. |
| 2020 | Acquisition of Strongbridge Biopharma | Expanded Xeris's portfolio to include rare disease products, diversifying its revenue streams and therapeutic focus. |
| 2021 | Gvoke auto-injector launch | Enhanced ease of use and patient convenience, driving increased adoption and market penetration for Gvoke. |
| 2023 | Continued growth in rare disease portfolio | Further solidified Xeris's presence in the rare disease market, contributing to revenue growth and pipeline expansion. |
| 2024 | Strategic collaborations and partnerships | Enabled Xeris to leverage external expertise and resources, accelerating the development and commercialization of innovative therapies. |
Xeris Biopharma's Transformative Moments
- Focus on innovative drug delivery technologies: Xeris has consistently focused on developing and commercializing ready-to-use injectable formulations, which has set it apart in the pharmaceutical industry.
- Strategic Acquisitions: The acquisition of Strongbridge Biopharma in 2020 significantly broadened Xeris's therapeutic scope and revenue base.
- Successful product launches: The successful development and launch of Gvoke auto-injector played a pivotal role in establishing Xeris as a key player in the diabetes market.
- Pipeline Expansion: Strategic investments in research and development have expanded Xeris's pipeline, positioning the company for sustained growth and innovation.
For more in-depth insights into Xeris Biopharma's investor profile, consider reading: Exploring Xeris Biopharma Holdings, Inc. (XERS) Investor Profile: Who’s Buying and Why?
Xeris Biopharma Holdings, Inc. (XERS) Ownership Structure
Understanding the ownership structure of Xeris Biopharma Holdings, Inc. provides valuable insights into the company's control and governance. The company's shares are held by a mix of institutional investors, individual shareholders, and company insiders.
Xeris Biopharma's Current Status
Xeris Biopharma Holdings, Inc. is a publicly traded company, meaning its shares are available for purchase on the open market. It is traded on the Nasdaq Global Select Market under the ticker symbol XERS.
Xeris Biopharma's Ownership Breakdown
The ownership of Xeris Biopharma is distributed among various types of shareholders. Here's a breakdown:
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Investors | 70.89% | Includes investment firms, mutual funds, and hedge funds. |
| Individual Investors | 27.84% | Shares held by individual investors. |
| Insiders | 1.27% | Shares held by company officers and directors. |
Xeris Biopharma's Leadership
The leadership team at Xeris Biopharma is responsible for the strategic direction and operational management of the company. Key members include:
- Paul R. Edick: Chairman and Chief Executive Officer
- Barry Deutsch: Chief Financial Officer
- Steven Pieper: Chief Scientific Officer
To gain more insight into the company's goals, check out Mission Statement, Vision, & Core Values of Xeris Biopharma Holdings, Inc. (XERS).
Xeris Biopharma Holdings, Inc. (XERS) Mission and Values
Xeris Biopharma is dedicated to enhancing patients' lives by developing and commercializing innovative solutions. The company's core values reflect a commitment to scientific rigor, patient-centricity, and a collaborative spirit.
Xeris Biopharma's Core Purpose
Official mission statement
While a specific, formally published mission statement for Xeris Biopharma Holdings, Inc. is not readily available in my knowledge sources, the company's activities and public statements suggest a mission focused on:
- Developing and commercializing ready-to-use injectable and infusible drug formulations.
- Improving patient outcomes and experiences through innovative drug delivery solutions.
- Focusing on therapies that address significant unmet medical needs.
Vision statement
Similarly, a specific vision statement is not formally published. However, based on Xeris Biopharma's strategic direction, a potential vision could be:
- To be a leader in innovative drug delivery, transforming the treatment landscape for chronic diseases.
- To expand access to critical medications through convenient and stable ready-to-use formulations.
- To drive significant advancements in patient care through novel therapeutic solutions.
Company slogan/tagline
I couldn't find an official slogan or tagline for Xeris Biopharma Holdings, Inc. However, considering their focus, a fitting tagline might emphasize their commitment to innovation and patient care.
For more in-depth information, check this link: Mission Statement, Vision, & Core Values of Xeris Biopharma Holdings, Inc. (XERS).
Xeris Biopharma Holdings, Inc. (XERS) How It Works
Xeris Biopharma Holdings, Inc. specializes in developing and commercializing ready-to-use injectable and infusible drug formulations that enhance patient care and outcomes, primarily focusing on endocrinology, neurology, and gastroenterology.
Xeris Biopharma's Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| Gvoke (glucagon injection) | Severe hypoglycemia in diabetes patients | Ready-to-use prefilled syringe and auto-injector, rapid glucose elevation, no reconstitution required |
| Recorlev (levoketoconazole) | Endogenous Cushing's syndrome | Inhibits cortisol production, oral medication, improves Cushing's symptoms |
| Keveyis (dichlorphenamide) | Primary Hyperkalemic Periodic Paralysis (HYPP) and Primary Hypokalemic Periodic Paralysis (HOPP) | Carbonic anhydrase inhibitor, oral tablet, reduces the severity and frequency of attacks |
| Ogluo (glucagon injection) | Severe hypoglycemia in diabetes patients (European Market) | Ready-to-use prefilled pen, rapid glucose elevation, no reconstitution required |
Xeris Biopharma's Operational Framework
Xeris Biopharma operates through a focused approach encompassing research and development, manufacturing, and commercialization. Their operational framework can be summarized as follows:
- Research and Development: Focuses on reformulating existing drugs into more convenient and stable forms, utilizing their XeriSol and XeriJect technology platforms.
- Manufacturing: Employs contract manufacturing organizations (CMOs) to produce their drug products, ensuring scalability and cost-effectiveness.
- Commercialization: Markets and sells its products through a dedicated sales force in the United States and through partnerships in other regions, such as Europe.
- Regulatory Affairs: Navigates the regulatory landscape to gain approvals for new products and maintain existing product licenses.
Xeris Biopharma's Strategic Advantages
Xeris Biopharma's strategic advantages stem from its innovative drug delivery technologies and focused market approach:
- Proprietary Technology Platforms: XeriSol and XeriJect technologies enable the development of stable, ready-to-use injectable and infusible formulations, providing a competitive edge.
- Niche Market Focus: Targeting specific medical conditions with unmet needs, such as diabetes-related hypoglycemia and Cushing's syndrome, allows for focused marketing and sales efforts.
- Strong Intellectual Property: Patents protecting their drug formulations and delivery technologies provide market exclusivity and protect against competition.
- Strategic Partnerships: Collaborations with other pharmaceutical companies and distributors expand their market reach and product portfolio.
To gain more insights into the financial aspects, you might find this resource helpful: Breaking Down Xeris Biopharma Holdings, Inc. (XERS) Financial Health: Key Insights for Investors
Xeris Biopharma Holdings, Inc. (XERS) How It Makes Money
Xeris Biopharma Holdings, Inc. primarily generates revenue through the commercialization of its proprietary products, which are primarily injectable and infusible drugs, and to a lesser extent through royalties and collaborations.
Xeris Biopharma Holdings, Inc.'s Revenue Breakdown
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Product Sales (Gvoke, Recorlev, Keveyis) | Approximately 94% | Increasing |
| Royalties and Collaboration Revenue | Approximately 6% | Varies based on partnership milestones and sales |
Xeris Biopharma Holdings, Inc.'s Business Economics
The company's business economics are shaped by several key factors:
- Proprietary Technology: Utilizes its XeriSol™ and XeriJect™ technology platforms to develop injectable and infusible therapies that are stable at room temperature, potentially reducing the need for refrigeration and improving ease of use.
- Pricing Strategy: Employs premium pricing for its branded products, reflecting the clinical benefits and convenience they offer compared to existing treatments.
- Market Access: Focuses on securing favorable reimbursement coverage from both commercial and government payers to ensure patient access to its therapies.
- Cost Management: Actively manages its operating expenses, including research and development, sales and marketing, and administrative costs, to improve profitability.
- Strategic Partnerships: Forms collaborations and licensing agreements with other pharmaceutical companies to expand its product portfolio and geographic reach.
Xeris Biopharma Holdings, Inc.'s Financial Performance
Key aspects of the company's financial performance include:
- Revenue Growth: Demonstrated strong revenue growth in recent years, driven by increasing sales of its key products, including Gvoke, Recorlev, and Keveyis. For example, total revenues for 2024 were $146.5 million, representing an increase of 34% compared to 2023.
- Gross Margin: Maintains a healthy gross margin, reflecting the value of its proprietary products and efficient manufacturing processes. The gross margin for 2024 was 63.3%.
- Operating Expenses: Invests significantly in research and development to advance its pipeline of new therapies. Operating expenses for 2024 totaled $128.9 million.
- Net Loss: Currently generates a net loss, reflecting its ongoing investments in research and development and commercialization activities. The net loss for 2024 was $47.9 million, an improvement compared to 2023.
- Liquidity and Capital Resources: Actively manages its liquidity and capital resources to fund its operations and growth initiatives. As of December 31, 2024, the company had cash, cash equivalents, and short-term investments totaling $123.1 million.
To gain a deeper understanding of the values that guide the company, explore Mission Statement, Vision, & Core Values of Xeris Biopharma Holdings, Inc. (XERS).
Xeris Biopharma Holdings, Inc. (XERS) Market Position & Future Outlook
Xeris Biopharma is strategically positioned to expand its presence in the pharmaceutical industry, focusing on innovative solutions and drug delivery technologies, which suggests a promising future outlook contingent on successful execution of its strategic initiatives and market dynamics.
Competitive Landscape
The competitive landscape for Xeris Biopharma is shaped by several key players, each holding a significant portion of the market share and leveraging unique competitive advantages. Here's an overview:
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Xeris Biopharma | Estimated at 3-5% | Specialized in ready-to-use injectable and infusible drug formulations with a focus on endocrinology and neurology. |
| Novo Nordisk | Approximately 45-50% | Dominates the diabetes care market with a broad portfolio of insulin and GLP-1 receptor agonists. |
| Eli Lilly | Around 25-30% | Strong presence in diabetes and obesity treatments, leveraging advanced research and development capabilities. |
Opportunities & Challenges
Xeris Biopharma faces a landscape of opportunities and risks that will significantly influence its growth trajectory.
| Opportunities | Risks |
|---|---|
| Expanding partnerships with other pharmaceutical companies to leverage Xeris's drug delivery technology for new therapeutic areas. | Intense competition from larger pharmaceutical companies with greater resources and established market presence. |
| Increasing demand for convenient and easy-to-use injectable therapies, particularly in diabetes and other chronic diseases. | Regulatory hurdles and delays in obtaining approvals for new drug formulations and delivery systems. |
| Growing market for orphan drugs and specialized treatments, where Xeris can focus its innovative capabilities. | Potential for product liability claims and recalls, which could damage the company's reputation and financial stability. |
Industry Position
Xeris Biopharma holds a unique position within the pharmaceutical industry, characterized by its focus on innovative drug delivery systems and specialized therapeutic areas.
- Specialized Focus: Xeris concentrates on developing and commercializing ready-to-use injectable and infusible drug formulations, differentiating itself from companies with broader portfolios.
- Innovative Technology: The company's XeriSol™ and XeriJect™ platforms offer potential advantages in terms of drug stability, ease of use, and patient compliance.
- Strategic Partnerships: Collaborations with other pharmaceutical companies can expand Xeris's reach and market penetration.
To gain more insights into the investors and motivations behind Xeris Biopharma, explore: Exploring Xeris Biopharma Holdings, Inc. (XERS) Investor Profile: Who’s Buying and Why?
Xeris Biopharma Holdings, Inc. (XERS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.